C12N 2710/10334
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/10334 (Use of virus or viral component as vaccine) appears on 89 US grants and 160 published applications in this corpus.
Search patents in C12N- Granted patents
- 89
- Published applications
- 160
- Assignees
- 94
- Inventors
- 264
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 0 |
| 2003 | 2 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 6 |
| 2009 | 0 | 4 |
| 2010 | 1 | 3 |
| 2011 | 0 | 3 |
| 2012 | 2 | 6 |
| 2013 | 0 | 5 |
| 2014 | 3 | 6 |
| 2015 | 2 | 4 |
| 2016 | 3 | 5 |
| 2017 | 6 | 11 |
| 2018 | 6 | 10 |
| 2019 | 7 | 12 |
| 2020 | 10 | 17 |
| 2021 | 5 | 8 |
| 2022 | 20 | 11 |
| 2023 | 7 | 15 |
| 2024 | 4 | 12 |
| 2025 | 7 | 10 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Zika/dengue vaccine and application thereof2 Jun 2026US 12,642,846 B2Institute of Microbiology, Chinese Academy of Sciences
- Rapid verification of virus particle production for a personalized vaccine2 Dec 2025US 12,487,241 B2NantBio, Inc.
- Vaccines for in vivo expression of nucleic acids and methods of using the same28 Oct 2025US 12,453,768 B2Orbis Health Solutions LLC
- Methods and compositions for producing an adenovirus vector for use with multiple vaccinations29 Jul 2025US 12,370,250 B2Etubics Corporation
- Recombinant adenoviruses and uses thereof27 May 2025US 12,312,382 B2Beth Israel Deaconess Medical Center, Inc.
- Methods for assessing resistance to non-integrating virus vectors27 Aug 2026US 2026/0250708 A1Université De Namur
- Vaccine6 Aug 2026US 2026/0224681 A1Oxford University Innovation Limited
- Method of reducing adenoviral vector-associated tts2 Jul 2026US 2026/0183353 A1Beth Israel Deaconess Medical Center, Inc.
- Combination treatment regimes for treating cancer2 Apr 2026US 2026/0091097 A1Barinthus Biotherapeutics North America, Inc.
- Virus-specific recombinant t cell receptors and t cells comprising them20 Nov 2025US 2025/0353892 A1Bar-Ilan University
Most cited
By later US patents
- Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof51US 9,217,159 B2The Trustees of the University of Pennsylvania · 2015
- Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof48US 8,834,863 B2The Trustees of the University of Pennsylvania · 2014
- Multivalent canine distemper virus vaccine26US 5,000,951 ADiamond Scientific Co. · 1991
- Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism19US 10,385,320 B2The Board of Trustees of the Leland Stanford Junior University · 2019
- Animal vaccines18US 3,950,512 APitman-Moore, Inc. · 1976